

Keywords: personalised medicine; gastric cancer; targeted therapies; growth factor receptors; predictive markers

HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma

Y J Liu^{1,3}, D Shen^{2,3}, X Yin¹, P Gavine¹, T Zhang¹, X Su¹, P Zhan¹, Y Xu¹, J Lv¹, J Qian¹, C Liu¹, Y Sun¹, Z Qian¹, J Zhang¹, Y Gu^{*,1,4} and X Ni^{*,2,4}

¹Department of Translational Science, Asia & Emerging Markets iMed, AstraZeneca R&D, 199 Liangjing Road, Shanghai 201203, China and ²Department of General Surgery, Renji Hospital, School of Medicine, Shanghai Jiao-Tong University, Shanghai 200127, China

Background: Gastric cancer (GC) is a leading cause of cancer deaths worldwide. Since the approval of trastuzumab, targeted therapies are emerging as promising treatment options for the disease. This study aimed to explore the molecular segmentation of several known therapeutics targets, human epidermal growth factor receptor 2 (HER2), MET and fibroblast growth factor receptor 2 (FGFR2), within GC using clinically approved or investigational kits and scoring criteria. Knowledge of how these markers are segmented in the same cohort of GC patients could improve future clinical trial designs.

Methods: Using immunohistochemistry (IHC) and FISH methods, overexpression and amplification of HER2, FGFR2 and MET were profiled in a cohort of Chinese GC samples. The correlations between anti-tumour sensitivity and the molecular segments of HER2, MET and FGFR2 alterations were further tested in a panel of GC cell lines and the patient-derived GC xenograft (PDGCX) model using the targeted inhibitors.

Results: Of 172 GC patients, positivity for HER2, MET and FGFR2 alterations was found in 23 (13.4%), 21 (12.2%) and 9 (5.2%) patients, respectively. Positivity for MET was found in 3 of 23 HER2-positive GC patients. Co-positivity for FGFR2 and MET was found in 1 GC patient, and amplification of the two genes was found in different tumour cells. Our study in a panel of GC cell lines showed that in most cell lines, amplification or high expression of a particular molecular marker was mutually exclusive and *in vitro* sensitivity to the targeted agents lapatinib, PD173074 and crizotinib was only observed in cell lines with the corresponding high expression of the drugs' target protein. SGC031, an MET-positive PDGCX mouse model, responded to crizotinib but not to lapatinib or PD173074.

Conclusions: Human epidermal growth factor receptor 2, MET and FGFR2 oncogenic driver alterations (gene amplification and overexpression) occur in three largely distinct molecular segments in GC. A significant proportion of HER2-negative patients may potentially benefit from MET- or FGFR2-targeted therapies.

Gastric cancer (GC) is among the leading causes of cancer deaths, and half of the worldwide cases occur within Eastern Asia (Ferlay *et al*, 2010). The majority of GC patients present with advanced

disease with a median overall survival of 8–10 months (Power *et al*, 2010). Despite significant advances in earlier diagnosis, surgical techniques and standard-of-care therapies, clinical outcome of GC

*Correspondence: Dr Y Gu; E-mail: yi.gu@astrazeneca.com or Professor X Ni; E-mail: niyin92@gmail.com

³Authors share co-first authorship.

⁴Authors share co-correspondence authorship.

Received 10 November 2013; revised 24 December 2013; accepted 8 January 2014; published online 11 February 2014

© 2014 Cancer Research UK. All rights reserved 0007–0920/14

remains dismal with a 5-year survival rate of ~20% (Kamangar *et al*, 2006). The development of novel, effective therapeutics for GC represents an urgent priority.

In the last decade, targeted therapies have emerged as a promising strategy for the treatment of GC. Trastuzumab, an mAb against human epidermal growth factor receptor 2 (HER2) (Fujimoto-Ouchi *et al*, 2007), was recently approved for the treatment of advanced HER2-positive GC patients as the result of the Trastuzumab for Gastric Cancer (ToGA) study (Bang *et al*, 2010). Positivity for HER2 in GC is defined by either a score of 3+ by immunohistochemistry (IHC) or with IHC 2+ plus HER2 amplification by FISH. The incidence of HER2 positivity in GC was ~15% (Janjigian *et al*, 2012; Kim *et al*, 2012), leaving a significant proportion whose clinical options are limited to standard chemotherapies. Additionally, a number of other receptor tyrosine kinases (RTKs), including EGFR, VEGFR, fibroblast growth factor receptor 2 (FGFR2) and hepatocyte growth factor receptor (MET), have been studied intensively to assess their therapeutic potential in GC (Meza-Junco and Sawyer, 2012; Pazo Cid and Anton, 2013). Therapies targeting VEGFR and EGFR have so far failed to translate their preclinical efficacy into prolonged patient survival in several late-stage trials for advanced GC (Ohtsu *et al*, 2011; Lordick *et al*, 2013; Waddell *et al*, 2013). All those trials lacked biomarker-assisted patient selection and *post hoc* analyses have yet to identify biomarker candidates that could help such selection (Khushalani, 2012). Meanwhile, for agents targeting FGFR2 and MET, predictive biomarkers have been identified in preclinical studies and early development, and the outlook for these inhibitors remains optimistic (Asaoka *et al*, 2011).

The FGFR2 RTK regulates cell proliferation, differentiation and motility and its frequent dysregulation, like gene amplification, is linked to tumour formation in GC (Turner and Grose, 2010; Xie *et al*, 2013). Fibroblast growth factor receptor inhibitors have demonstrated preclinically that *FGFR2* amplification confers hypersensitivity to FGFR2 inhibition in GC (Nakamura *et al*, 2006; Xie *et al*, 2013). AZD4547 and dovitinib are two such anti-FGFR2 therapies that have progressed to mid-late stage trials in advanced GC patients (NCT01457846 and NCT01719549). Both programs have adopted *FGFR2* amplification as patient selection; although the detection techniques are different – the AZD4547 trial employs FISH and the dovitinib trial uses RT-PCR.

MET is also well documented for its role in cell proliferation and invasion, and its dysregulation contributes to tumour growth and metastasis (Sierra and Tsao, 2011). *MET* amplification and protein overexpression, which can lead to constitutive activation of the MET pathway, are associated with shorter survival in GC patients (Lee *et al*, 2012). This increased understanding has led to the development of several MET signalling pathway inhibitors including MetMab, rilotumumab (AMG102) and MET TKIs such as tivantinib (Eder *et al*, 2009). For these MET signalling pathway inhibitors, finding predictive biomarkers early in clinical development is critical (Brunetto *et al*, 2010). Earlier phase II trials of tivantinib and MetMab in NSCLC patients showed that MET overexpression rather than *MET* amplification could be useful in enriching patients (Spigel *et al*, 2011; Rodig *et al*, 2012). Indeed, patients who were negative for MET expression performed worse on MetMab when compared with chemotherapy alone, highlighting the potential for both positive enrichment and negative exclusion. An ongoing phase III trial (NCT01662869) of MetMab in HER2-negative GC patients utilises MET protein overexpression by IHC as patient selection. Encouragingly, the HGF-targeted antibody rilotumumab demonstrated clinical benefit when used in combination with chemotherapy in a phase II gastric/oesophageal trial (Oliner *et al*, 2012). Similarly, patients with tumours scoring 'MET-high' by IHC assay (defined as '>50% of tumour cells positive') performed significantly better on drug (OS 11.1 vs 5.7 months, HR = 0.29 compared with chemotherapy alone) when

compared to patients with tumours scored as 'MET-low' (defined as '≤50% tumour cells positive') who had a trend towards unfavourable survival using the rilotumumab/chemotherapy combination compared with chemotherapy alone (HR = 1.84).

The oncogenic alterations in HER2, MET and FGFR2 have rarely been studied simultaneously in the same patient cohort using clinically validated or investigational assays and scoring criteria (Ming, 1998). Previous efforts have mainly focused on the profiling of single biomarkers within individual cohorts (Kim *et al*, 2012; Lee *et al*, 2012; Matsumoto *et al*, 2012). The most comprehensive profiling of GC to date has employed high-resolution single-nucleotide polymorphism arrays (Deng *et al*, 2012). Unlike most other cancers, mutations and epigenetic changes in *HER2*, *MET* and *FGFR2* are rarely observed in GC (Asaoka *et al*, 2011). Furthermore, protein overexpression and/or amplification of *HER2*, *MET* and *FGFR2* are confirmed as oncogenic driver alterations in GC. Therefore, IHC and FISH are strongly supported as diagnostic platforms for these targeted therapies.

With MET and FGFR2 inhibitors currently progressing into late-stage GC trials, there is a need to better understand molecular segmentation of *MET*, *FGFR2* and *HER2* alterations within GC (Nadauld and Ford, 2013). Such knowledge will be particularly useful in the application of patient selection strategies, and also in potentially understanding *de novo* resistance in response to these targeted therapies (Nadauld and Ford, 2013).

Here, we analysed 172 Chinese GC patients for protein expression and gene amplification of *HER2* and *MET*, using a combination of validated IHC and FISH methods. *FGFR2* amplification within the same cohort was recently reported (Xie *et al*, 2013). Together, we identified HER2-negative GC populations that could potentially benefit from FGFR or MET inhibitors. To further investigate this, we profiled a panel of GC cell lines for high expression and amplification of *MET*, *HER2* and *FGFR2*, and demonstrated highly selective *in vitro* growth-inhibitory effects using agents specifically targeting the three proteins. Furthermore, we showed the ability of an MET TKI to potentially inhibit tumour growth in a patient-derived GC xenograft (PDGCX) model with *MET* amplification and overexpression.

MATERIALS AND METHODS

Patients and tumour samples. This study included 253 patients with GC who underwent surgery between 2007 and 2011 at the Renji Hospital, Shanghai, China (Table 1). Adjuvant chemotherapies were administered to 143 patients; 43 patients received no chemotherapy; and chemotherapy status for the remaining 65 patients was not available. Histological subtype according to Lauren's classification was determined after a review of tumour sections by two trained pathologists. Follow-up data were available from 202 patients, who were assessed at 3, 6 and 12 months and then every 6 months for 5 years or until death. This study was approved by Renji Hospital institutional review board.

Immunohistochemistry. Immunohistochemistry analyses were performed on tissue microarray (TMA) at 4 μm thickness. For HER2 staining, a HercepTest kit (DAKO, Glostrup, Denmark) was used following the manufacturer's instructions. The MET staining was performed using a rabbit monoclonal anti-total MET antibody (SP44; Ventana Medical Systems, Oro Valley, AZ, USA) on an automatic immunostainer (Discovery XT; Ventana Medical Systems).

The DAKO HercepTest guideline was used to semi-quantitatively score MET and HER2 expression. To minimise the impact of intratumoral heterogeneity of HER2 expression, case-matched whole sections of HER2-negatively scored TMA samples were re-evaluated.

Table 1. Characteristics of patients with gastric carcinoma

Factors	N	%
Age, years		
≤Median (63)	125	49
>Median (63)	128	51
Gender		
Male	176	69
Female	77	31
Histologic grade		
1	3	1
2	50	20
3	173	69
4	26	10
Clinical stage		
1	18	7
2	59	24
3	128	51
4	47	19
Histologic type		
Intestinal	78	31
Diffuse	171	69
T		
1	8	3
2	24	10
3	206	82
4	14	6
N		
0	64	25
1	112	45
2	46	18
3	30	12
M		
0	231	92
1	21	8

All slides were independently evaluated and agreed by two pathologists who were blind to patients' data.

FISH. The dual-colour FISH assay used the *HER2/CEP17* probes from Vysis (Chicago, IL, USA; Cat #30-171060) and the *MET* probe from labelling BAC (CTD-2270N20) DNA with Red-dUTP (Enzo Biochem, Farmingdale, NY, USA; Cat #02N34-050). *CEP10*-Spectrum Green probe (Vysis, Cat #32-112010) and *CEP7*-Spectrum Green probe (Vysis, Cat #32-132007) for the centromeric regions of chromosomes 10 and 7 were used as internal controls of *FGFR2* and *MET* probes, respectively. Detailed procedures were previously described (Xie *et al*, 2013).

Detailed experimental method for multi-colour FISH was included in Supplementary information.

Criteria for defining biomarker positivity. *HER2* + cases were defined by IHC 3 + or IHC 2 + plus *HER2* amplification. *MET* + cases were defined by IHC 2 +/3 + according to the patient selection criteria of the ongoing MetMAB trial in GC (NCT01662869). *FGFR2* + cases were defined by *FGFR2* amplification according to the ongoing trials of AZD4547 and dovitinib in GC (NCT01457846 and NCT01719549).

In vitro cell proliferation. Anti-proliferative activity was measured as described previously using standard metabolism-based anti-proliferative assays (Davies *et al*, 2007). Each experiment was carried out in triplicate and data presented as geometric means. All the cell lines were profiled by affymetrix (details in Supplementary information), IHC and FISH.

In vivo anti-tumour efficacy and pharmacodynamics. The PDGCX mouse models were established by implanting fresh surgical human tumour tissue into immunodeficient mice. Animals were housed in a specific pathogen-free animal facility in accordance with the Guide for Care and Use of Laboratory Animals (eighth edition) and the regulations of the Institutional Animal Care and Use Committee (IACUC). All animal studies were approved by the IACUC. Briefly, PDGCX tissue fragments (~15 mm³) were implanted subcutaneously into 8- to 10-week-old female nude mice (Vital River, Beijing, China). Tumour-bearing mice with a tumour size of 150–250 mm³ were randomly divided into vehicle or treatment groups (five animals per group). Subcutaneous tumours and mice body weight were measured twice a week with caliper and balance. Tumour volumes (TVs) were calculated by the formula: TV = (length × [width]²)/2. The percentage of tumour growth inhibition (%TGI) was calculated by the formula: TGI% = [1 - (changes of TV in treatment group/changes of TV in control group)] × 100. For tumour regression, in which the TV after treatment was smaller than the TV at the beginning, the following equation was used: regression% = 100 × (T₀ - T_i)/T₀. T₀ and T_i are TV in the same group but measured at the different time points. T₀ is TV on the day before first treatment and T_i is TV on the last measurement day after treatment. Statistical significance was evaluated using a one-tailed, two sample *t*-test. *P* < 0.05 was considered as statistically significant.

Antibodies and immunoblotting. Primary antibodies for total-MET, p-MET(Tyr1234/1235), p-Erk(Thr202/Tyr204), Erk, AKT, GAPDH, as well as secondary anti-rabbit and mouse antibodies were purchased from Cell Signaling Technology (Danvers, MA, USA). The primary antibody for p-AKT (Ser473) was purchased from DAKO. The vehicle and crizotinib-treated tumours (collected 2-h post treatment) were grinded in liquid nitrogen and lysed in ice-cold RIPA buffer (Thermo Scientific, Waltham, MA, USA). The protein concentration was determined by BCA (Pierce, Rockford, IL, USA). In all, 80 µg of tumour extracts was separated in NuPAGE gel (Invitrogen, Camarillo, CA, USA) under reducing conditions and transferred onto nitrocellulose membranes by iBlot gel transfer stack (Invitrogen). After blocking and antibody incubation, the membrane was exposed by ECL followed by western blotting detection system (GE Health, Waukesha, WI, USA). The signals were captured by LAS400 imaging system (Fujifilm Life Science, Valhalla, NY, USA).

Statistical analysis. The analysis was conducted using R version 2.10.1 (<http://cran.r-project.org/bin/windows/base/old/2.10.1/>). Characteristics of the two groups were compared using the χ^2 -test. Correlation of protein expression and gene amplification of a biomarker is assessed using *Kappa* statistics. Logistic regression model was applied to interrogate association of biomarker data and individual clinical parameter. The Kaplan–Meier method was used to estimate the survival distributions. The log-rank test was used to compare the survival distributions. Two-sided *P*-values < 0.05 were considered as statistically significant.

RESULTS

Patient information and tumour characteristics. Of the 253 Chinese GC patients evaluated in this study, all had undergone total or subtotal gastrectomy with lymphadenectomy, according to

the tumour location. Detailed patient information and tumour characteristics are listed in Table 1. Pathologically, these tumours were all gastric adenocarcinomas representing intestinal and diffused subtypes, according to Lauren's classification. The percentages of the clinical stages according to WHO TNM classification were stage I, 7%; stage II, 24%; stage III, 51%; stage IV, 19%. Patient survival data were available for 202 patients and the median survival time was 28 months (range 0–55). Patients with more advanced clinicopathological features such as tumour grade and clinical stage were associated with worse survival (data not shown).

HER2 positivity in Chinese GC patients. To evaluate the prevalence of HER2 positivity in these Chinese GC samples, we performed IHC and FISH analysis following the current clinical practice for HER2-targeted therapies in advanced GC patients. A total of 221 patient samples were studied for membranous expression of HER2 by IHC using a 'HercepTest' kit. The percentage breakdown of HER2 IHC scores was as follows: 0, 58.4%; 1+, 16.7%; 2+, 14.0%; 3+, 10.9%. Among these, 55 samples exhibited HER2 protein overexpression with IHC scores of 2+ and 3+ (Table 2; Figure 1A). HER2 FISH analysis was also performed on 219 out of the IHC-analysed 221 patient samples, and showed an amplification rate of 15.0% (Table 2; Figure 1B). The remaining two cases that were not evaluated by FISH assay had IHC scores of 0, and hence based on ToGA trial criteria Bang

et al (2010) required no further FISH confirmation of their HER2 status. Furthermore, HER2 amplification was found in 25 (45.5%) of 55 patients with HER2 overexpression, but only in 8 (4.9%) of 164 patients with HER2 IHC scores of 0 or 1+. This suggests that HER2 amplification shows a good concordance ($\kappa = 0.514$) with protein overexpression in these GC samples (Table 2).

Taken together, HER2+ status was detected in 33 (14.9%) of 221 GC patient samples studied (Table 2). Similar to the findings from the ToGA trial (Bang *et al*, 2010), a higher incidence of HER2+ was found in the intestinal subtype (28.0%) as compared with the diffuse subtype (8.3%). Human epidermal growth factor receptor 2 overexpression and HER2 amplification were not found to be significantly ($P > 0.1$) associated with patient survival.

MET gene amplification and protein overexpression in Chinese GC patients. Next, we evaluated the prevalence of MET amplification and overexpression and their concordance correlation in the same Chinese GC cohort. The MET protein overexpression (as defined by IHC 2+ or 3+) was identified in 26 (12.3%) of 212 patients (Table 2; Figure 1D). The FISH analysis detected MET amplification in 12 (6.1%) of 196 patient samples (Table 2; Figure 1E). Among the 176 patient samples analysed by both IHC and FISH, MET overexpression was found in 9 out of the 12 MET-amplified cases, suggesting a markedly high correlation ($\kappa = 0.674$) between MET gene amplification and protein

Table 2. Rates of HER2, FGFR2 and MET gene amplification, protein overexpression and biomarker positivity in Chinese GC

Biomarker	Gene amplification	Protein overexpression ^a	κ^b	Biomarker + ^c
HER2	15.0% (33/219)	24.9% (55/221)	0.514	14.9% (33/221)
FGFR2	5.1% (10/198) ^d	n/a	n/a	5.1% (10/198)
MET	6.1% (12/196)	12.3% (26/212)	0.674	12.3% (26/212)

Abbreviations: FGFR2=fibroblast growth factor receptor 2; FISH=fluorescence *in situ* hybridisation; GC=gastric cancer; HER2=human epidermal growth factor receptor 2; IHC=immunohistochemistry; MET=hepatocyte growth factor receptor.

^aProtein overexpression: IHC score ≥ 2 .

^bCorrelation of gene amplification with protein overexpression for HER2 and MET.

^cBiomarker +: HER2+, IHC score = 3 or IHC score = 2 plus gene amplification by FISH; FGFR2+, gene amplification by FISH; MET+, IHC score ≥ 2 .

^dPreviously published by Xie *et al* (2013).




Figure 1. Representative GC cases with overexpression and amplification of HER2, MET and FGFR2. (A and B) Strong membrane staining (IHC 3+) and gene amplification by FISH (red signal, HER2; green signal, CEP17) of HER2. (C) Gene amplification by FISH (red signal, FGFR2; green signal, CEP10) of FGFR2. (D, E) Strong membrane staining (IHC 3+) and gene amplification by FISH (red signal, MET; green signal, CEP7) of MET.

overexpression (Table 2). In addition, we found that both *MET* amplification and *MET* overexpression were significantly associated with more frequent lymph-node metastasis ($P=0.01$ and 0.02 , respectively (X^2)) and distant metastasis ($P=0.01$ and 0.03 , respectively (X^2)). Patients with *MET*-amplified tumours had significantly poorer survival than patients with non-amplified tumours ($P=0.0012$; Figure 2A). Similarly, patients with tumours scoring *MET* IHC 3+ were also found to be significantly associated with shorter survival time, compared to patients with tumours scoring <IHC3+ ($P=0.001$; Figure 2B).

Chinese GC patient tumours exhibit distinct molecular segments of *HER2*, *FGFR2* and *MET* alterations. Besides the




Figure 2. *MET* amplification and overexpression leads to worse survival in GC patients. (A) Association of *MET* amplification with survival time in 164 GC patients. Median survival time was 10.5 months for patients with *MET* amplification compared with 48 months for patients with non-amplified *MET*. The difference was significant in the log-rank test ($P=0.0125$). (B) Association of *MET* IHC 3+ with survival time in 167 GC patients. Median survival time was 8 months for patients with *MET* IHC 3+ compared with 45 months for patients without *MET* IHC3+. The difference was significant in the log-rank test ($P=0.0013$).

HER2 and *MET* oncogenic alterations, abnormal activation of *FGFR2* signalling via gene amplification has also been recently identified as a potential oncogenic driver in advanced GC patients (Xie *et al*, 2013). As we previously observed in the same Chinese GC cohort, *FGFR2* amplification (Table 2; Figure 1C) was detected in 10 (5.1%) of 198 patients.

To further evaluate the exclusivity and/or concordance correlation among the three molecular markers within this GC cohort, a total of 172 patients were stratified according to their *HER2*, *MET* and *FGFR2* positivity status (refer to Materials and methods for criteria of biomarker positivity). As summarised in Figure 3, the percentages of positive patients for each molecular segment were *HER2*+, 13.4%; *MET*+, 12.2% and *FGFR2*+, 5.2%. Among these positive patients, no patient was found to be positive for all three biomarkers. Furthermore, *FGFR2*+ did not overlap with *HER2*+ in this cohort. Of particular interest, *MET*+ overlapped with *FGFR2*+ in one case from the *HER2*-negative population, accounting for 11.1% (1 out of 9) of *FGFR2*+ patients or 0.6% (1 out of 172) of all patients. *MET*+ also overlapped with *HER2*+ in 3 cases, accounting for 13.0% (3 out of 23) of *HER2*+ patients or 1.7% (3 out of 172) of all patients (Figure 3). In summary, the percentage of samples exclusively staining positive for a single marker (i.e., no overlap) is as follows: *HER2*+ alone, 87.0% (20 out of 23); *MET*+ alone, 81.0% (17 out of 21); *FGFR2*+ alone, 88.9% (8 out of 9). Together, our results from 172 Chinese GC patients suggest that *HER2*, *MET* and *FGFR2* oncogenic alterations occur in three largely distinct molecular segments.

***FGFR2* and *MET* gene amplifications exist in different tumour cells from an *FGFR2*+/*MET*+ Chinese GC patient.**

We developed *FGFR2*/*MET* multi-colour FISH assay and analysed the whole tumour section from case number GC122T, which is the only case that showed co-amplification of more than one gene among the four overlapping cases (three cases for *MET*+/*HER2*+ and one case for *FGFR2*+/*MET*+). This case showed gene amplifications for both *FGFR2* (average copy number 5.22, *FGFR2*/*CEP10* ratio 2.2) and *MET* (average copy number >20, *MET*/*CEP7* ratio>4). Both genes exhibited clustered signals, and the two amplifications appeared in different tumour cells (Figure 4).




Figure 3. *HER2*, *MET* and *FGFR2* oncogenic driver alterations occur in distinct molecular segments in GC. The percentages of positive patients for each biomarker are as follows: *HER2*+, 13.4% (23 out of 172); *FGFR2*+, 5.2% (9 out of 172); *MET*+, 12.2% (21 out of 172). No patient was recorded to be positive for all three biomarkers. One case was found to be positive for both *MET* and *FGFR2*. Three patients were found to be positive for both *HER2* and *MET*.




Figure 4. *MET* and *FGFR2* genes were co-amplified but in different tumour cells from case GC122T. The top lane shows the tumour cell with *MET* (red signal) amplification (A), *FGFR2* (gold signal) trisomy (B) and their merged image (C). The lower lane shows another tumour cell with *MET* polysomy (D), *FGFR2* amplification (E) and their merged image (F). Green and aqua signals represent *CEP7* and *CEP10*, respectively.

GC cell lines carrying *HER2*, *MET* and *FGFR2* oncogenic alterations are sensitive to drugs targeting the corresponding pathways. To explore *in vitro* drug sensitivities of cell lines expressing the various molecular aberrations highlighted above, a panel of 24 GC cell lines were exposed to drugs targeting *FGFR2* (PD173074, *FGFR2* phosphorylation IC_{50} ~10 nM) (Kunii *et al*, 2008), *HER2* (Lapatinib, *HER2* enzyme IC_{50} 9.2 nM) (Rusnak *et al*, 2007) and *MET* (crizotinib, *MET* enzyme IC_{50} 6 nM) (Timofeevski *et al*, 2009). Standard metabolism-based anti-proliferative assays were performed following 3 days drug exposure and 50% growth inhibition (GI_{50}) values were determined. In parallel, mRNA expression analysis was performed on *HER2*, *MET* and *FGFR2*, and absolute mRNA probe signal values were used to determine correlations with anti-proliferative responses to these targeted therapies (Table 3). Notably, anti-proliferative response to crizotinib showed an excellent correlation with the levels of *MET* mRNA and its protein expression, with cell lines GTL16, Hs746t, SNU-5, SNU-620 and SNU-638 displaying crizotinib GI_{50} values ranging from 6 to 30 nM which all display *MET* mRNA probe values of >1000, *MET* amplification and high protein expression (IHC3+). All other cell lines showed minimal response to crizotinib (GI_{50} values >0.13 μ M) and correspondingly had low *MET* mRNA expression (probe values <250), no *MET* amplification and undetectable protein expression (IHC0). Similarly, strong anti-proliferative responses to lapatinib were only achieved in cell lines NCI-N87 and NUGC-4 (GI_{50} values of 16 and 69 nM, respectively), both of which showed *HER2* mRNA probe values of >1000 and high expression of *HER2* protein (IHC2+/3+, with NCI-N87 also showing *HER2* amplification). Finally, exposure to PD173074 resulted in potent anti-proliferative responses in cell lines KATO-III and SNU-16 (GI_{50} values of 79 and 92 nM, respectively), both of which are known to be *FGFR2* gene amplified and exhibit *FGFR2* mRNA probe values of >1000.

Of particular interest, none of the GC cell lines showed strong anti-proliferative responses to all three drugs, and indeed, in each

of the responding cell lines, a strong anti-proliferative response was only achieved using a single drug.

***MET* gene amplification and protein overexpression in a PDGFCX mouse model predict selective sensitivity to *MET* inhibitor.** To further explore the translational significance of above findings, we selected a PDGFCX mouse model (SGC031) harbouring *MET* amplification and *MET* overexpression (IHC 3+), but no gene amplification and/or protein overexpression of *FGFR2* and *HER2*. To assess anti-tumour efficacy of an *MET* inhibitor in this model, SGC031 tumour-bearing nude mice were treated with crizotinib 50 mg kg⁻¹, Lapatinib 100 mg kg⁻¹, PD173074 50 mg kg⁻¹, docetaxel 10 mg kg⁻¹, or the combination of crizotinib and Docetaxel, respectively. Once-daily administration of crizotinib gave statistically significant tumour regression of 89% ($P < 0.0001$) when compared with vehicle controls (Figure 5A). In contrast, chronic oral treatment with PD173074, an *FGFR* inhibitor, or lapatinib, an *HER2* inhibitor did not result in significant TGI over the same period of treatments (14% and 17% TGI, respectively, all values $P \geq 0.2$). Once weekly intravenous administration of docetaxel showed tumour regression (19% tumour regression, $P < 0.0001$) during treatment period and importantly, combined treatment with crizotinib did not result in antagonism compared with crizotinib monotherapy alone (81% tumour regression, $P < 0.0001$). Downregulation of p-*MET* (Y1234/1235) as well as its downstream targets, p-AKT (Ser473) and p-ERK (Thr202/Tyr204) in SGC031 tumour post-crizotinib treatment was observed by immunoblotting (Figure 5B).

DISCUSSION

Since the approval of trastuzumab, it is increasingly clear that targeted therapies can provide survival benefit in advanced GC patients (Bang *et al*, 2010). Targeted therapies rely on design and

Table 3. *In vitro* sensitivity with respect to mRNA gene expression and biomarker positivity by IHC/FISH

Cell line	mRNA expression by Affymetrix			Biomarker positivity by IHC/FISH			<i>In vitro</i> anti-proliferative GI ₅₀ (nM)		
	FGFR2	HER2	MET	FGFR2 (FISH)	HER2 (IHC/FISH)	MET (IHC/FISH)	PD173074	Lapatinib	Crizotinib
SNU-620	193.5	329.3	2496.5	Non-amp	0/non-amp	3/AMP	> 10 000	5949	16.4
SNU-5	20.0	468.0	2265.6	Non-amp	0/non-amp	3/AMP	> 10 000	> 10 000	5.5
Hs 746T	20.0	137.7	1977.5	Non-amp	0/non-amp	3/AMP	1580	9853	12.6
GTL16	349.9	277.0	1219.8	Non-amp	0/non-amp	3/AMP	> 10 000	7861	29.8
SNU-638	20.0	310.8	1154.0	Non-amp	0/non-amp	3/non-amp	4359	2376	12.2
PAMC82	41.8	128.7	255.8	Non-amp	0/non-amp	1/non-amp	> 10 000	> 10 000	8254
IM95m	81.3	302.3	209.5	Non-amp	2/non-amp	0/non-amp	5471	2445	133
NUGC-3	20.0	164.2	184.7	Non-amp	0/non-amp	0/non-amp	> 10 000	2024	5785
OCUM-1	617.3	402.4	132.1	Non-amp	0/non-amp	1/non-amp	> 10 000	> 10 000	974
SNU-601	134.3	530.3	126.2	Non-amp	1/non-amp	0/non-amp	6317	4451	2762
NUGC-4	297.1	1006.5	535.0	Non-amp	2/non-amp	2/non-amp	> 10 000	69.2	4575
NCI-N87	58.9	9373.6	416.5	Non-amp	3/AMP	0/non-amp	> 10 000	15.6	5374
SNU-216	385.7	1989.8	322.3	Non-amp	3/AMP	2/non-amp	> 10 000	1398	5386
MKN1	20.0	195.2	97.2	Non-amp	0/non-amp	0/non-amp	> 10 000	3566	2090
SNU-1	105.5	268.1	92.8	Non-amp	0/non-amp	0/non-amp	2355	2266	666
MKN74	87.3	174.2	91.7	Non-amp	0/non-amp	0/non-amp	> 10 000	7743	4754
HGC-27	177.1	249.8	67.1	Non-amp	0/non-amp	0/non-amp	7968	3203	694
23132/87	65.2	356.7	47.6	Non-amp	0/non-amp	0/non-amp	> 10 000	4267	1717
AGS	85.4	305.7	45.2	Non-amp	0/non-amp	0/non-amp	3157	> 10 000	1430
SNU-484	20.0	832.9	33.3	Non-amp	1/non-amp	0/non-amp	> 10 000	1049	2400
AZ-521	465.2	339.6	22.7	Non-amp	2/non-amp	0/non-amp	> 10 000	9993	1825
KATO III	1955.7	341.0	614.0	AMP	1/non-amp	0/non-amp	79.0	> 10 000	3122
SNU-16	7180.4	280.0	89.5	AMP	1/non-amp	0/non-amp	91.6	5002	973

Abbreviations: AMP = amplification; FGFR2 = fibroblast growth factor receptor 2; FISH = fluorescence *in situ* hybridisation; GI₅₀ = 50% growth inhibition; HER2 = human epidermal growth factor receptor 2; IHC = immunohistochemistry; MET = hepatocyte growth factor receptor; mRNA expression = mRNA absolute probe values, highlighted in bold when greater than 1000; non-amp = non-amplification.

For biomarker positivity, IHC score 3+ or FISH AMP cell lines are highlighted in bold. Associations between gene mRNA level, protein expression and corresponding drug sensitivity are highlighted using lightly shaded (MET/crizotinib), moderately shaded (HER2/lapatinib) and darkly shaded (FGFR2/PD173074) cells. Note that for *in vitro* anti-proliferation testing, GI₅₀ values (50% growth inhibitory drug concentration) below 100 nM are regarded as highly potent.

execution of a personalised medicine strategy, which depends on a good knowledge of how oncogenic driver markers are expressed in the same set of patient samples (Nadauld and Ford, 2013). To ensure the success of future targeted therapies, it is imperative to understand the molecular segmentation of key 'druggable' targets within GC. Currently besides HER2, targeting approaches to MET and FGFR2 are most clinically advanced. MetMab and rilotumumab, monoclonal antibodies targeting MET and HGF respectively, are currently being tested in phase III GC trials and are utilising MET overexpression by IHC as a patient selection approach; meanwhile, dovitinib and AZD4547, two FGFR TKIs, use *FGFR2* amplification by RT-PCR and FISH in their phase II GC trials. Our study here, by using the diagnostic methods that are currently employed for patient selection in MET- and FGFR-targeted GC trials, is the first to comprehensively characterise *HER2*, *MET* and *FGFR2* oncogenic alterations in a cohort of GC patient samples.

Our data showed that HER2+, MET+ and FGFR2+ represent three largely distinct molecular segments, with slight overlap between HER2+ and MET+ patients (1.7% GC) and between MET+ and FGFR+ (0.6% GC). In addition, our results confirmed the reported findings on Chinese GC patients that HER2+ rate is 10–15% (Shan *et al*, 2013; Sheng *et al*, 2013). It is worthwhile to mention that we took consideration of GC tumour

heterogeneity, by confirming (on whole tissue sections) the IHC status of those cases (on TMAs) that were HER2 negative. On the other hand, MET protein expression is much less documented in Chinese GC. Recently, Lee *et al* (2012) analysed a Korean GC population and characterised the incidence of MET overexpression and amplification at 23.7% and 3.4%, respectively. Using identical methodologies, we found a lower protein overexpression rate (12.3%) and a slightly higher amplification rate (6.1%). Despite these slight discrepancies, the findings from these two data sets are largely consistent. Namely, in both data sets MET IHC 3+ and MET amplification were associated with poor prognosis, and MET amplification was highly associated with MET protein overexpression. These data, when combined with our previous *FGFR2* amplification results in the same sample cohort (Xie *et al*, 2013), suggest that ~15% of HER2-negative GC patients could potentially benefit from FGFR2- or MET-targeted agents. Data from Graziano *et al* (2011) demonstrate a link between poor prognosis and elevated MET gene copy number (GCN) in radically resected GC patients; however, an absence of robust correlative data between patient tumour MET GCN and protein expression, combined with the prevalence of clinical IHC diagnostic assays suggests that measurement of protein levels appears to be a favoured emerging clinical approach. In addition to the clinical GC




Figure 5. Crizotinib displays potent anti-tumour efficacy in an MET amplification and overexpression PDGXC model. **(A)** SGC031-bearing nude mice were treated with vehicle, lapatinib 100 mg kg⁻¹ bid, or crizotinib 50 mg kg⁻¹ qd, or PD173074 50 mg kg⁻¹ qd or docetaxel 20 mg kg⁻¹ twice weekly alone, or the combination of crizotinib and docetaxel, respectively, for 3 weeks. Tumour volume was measured at the time indicated. Statistical analysis of tumour growth inhibition was performed using a Student's *t*-test; *p* < 0.0001. **(B)** Downregulations of p-MET (Y1234/1235), p-AKT (Ser473) and p-ERK (Thr202/Tyr204) were observed in crizotinib-treated SGC031 tumours by immunoblotting. Total-AKT, MET and ERK levels remained unchanged.

responses already described using MetMab and rilotumumab, the small-molecule EML4-ALK and MET inhibitor, crizotinib, has also shown evidence of efficacy in MET-driven tumours (Lennerz *et al*, 2011). Within a phase I crizotinib expansion study, four patients were identified with focally gene amplified MET gastric or oesophageal junction tumours, two of whom experienced tumour shrinkage upon crizotinib treatment. In keeping with our data, the authors also demonstrated that *HER2* and *MET* were, with one exception, mutually exclusive in a cohort of 489 patient samples. In this instance, co-amplification was observed between *MET* and *EGFR*.

Our profiling of a panel of GC cell lines for their DNA, mRNA and/or protein expressions of *HER2*, *MET* and *FGFR2* revealed a molecular segmentation profile similar to that of the surgical samples. In most cell lines, amplification or high expression of each marker was mutually exclusive and *in vitro* sensitivity to the targeted agents lapatinib, PD173074 and crizotinib was only observed in cell lines with the corresponding high expression of the drugs' target. These data support the notion of 'oncogenic drivers', whereby tumour cells evolve a reliance on a particular oncogenic pathway. Furthermore, we extended the translational significance of these findings by exploring *in vivo* sensitivity of an MET amplification and overexpression PDGXC model to drugs targeting the three biomarkers of interest. Our data showed tumour dependence on MET signalling with sensitivity to crizotinib and non-response to drugs targeting *HER2* or *FGFR2*, thus validating targeting of this particular segment through use of a PDGXC

model. One exception to above findings is the highly *HER2*-expressing cell line, SNU-216. Despite showing high expression of *HER2* (IHC 3+), this line was relatively unresponsive to lapatinib, likely as a consequence of elevated *MET* expression. Indeed, co-expression of *MET/HER2* proteins was observed in SNU-216 cell and its insensitivity to lapatinib has also been observed by Chen *et al* (2012), who concluded that *MET* upregulation abrogates the inhibitory effect of lapatinib.

On the basis of clinical experience, patient selection is critical in ensuring the efficacy of inhibitors targeting oncogenic drivers. Nevertheless, even within biomarker-positive patients, initial response rates can vary (*de novo* resistance) and more importantly, secondary (acquired) resistance ultimately occurs in the majority of cancer patients. In *HER2*+ breast cancer patients, the rate of primary resistance to single-agent trastuzumab is around 66–88% and the majority of the responding patients develop secondary resistance within a year (Nahta and Esteva, 2006). In the ToGA trial, *HER2*+ GC also showed a low complete response rate (Bang *et al*, 2010). Previous studies (Minuti *et al*, 2012; Oliveras-Ferreros *et al*, 2012), together with our results of SNU-216's poor response to lapatinib or crizotinib, suggest that co-activation of the *MET* pathway could cause low or no response to *HER2*-targeted therapies. As our study indicates *MET* overexpression in 14% of *HER2*+ patients, we speculate that *MET* expression could potentially be a contributing factor to the low response rates observed in clinic. In addition, we used multi-colour FISH to analyse the overlapping *MET*+ and *FGFR2*+ patient sample and found that the two genes were co-amplified. This is the first reported case of co-amplification of *MET* and *FGFR2* in a GC patient, though such co-amplification event appears rare (0.6% of all GC). In this case, co-amplification found in different tumour cells clearly explains tumour heterogeneity in GC. However, the limitation to this study is that we were unable to verify which class of inhibitor such patient would potentially receive optimal therapeutic benefit from; while future studies aim to identify co-expressing PDGXC models to enable preclinical testing.

In summary, this study profiled the expression of key oncogenic drivers in a cohort of GC patient samples and a panel of GC cell lines. Our data demonstrated that these markers show largely distinct molecular segments within GC and suggest that a significant proportion of *HER2*-negative GC patients could benefit from *FGFR2*- and *MET*-targeted therapies.

ACKNOWLEDGEMENTS

We thank Li Zheng for pathological review, Joan Fan for FISH probes, Lin Zhang and Xie Liang for PDGXC model establishment.

CONFLICT OF INTEREST

The authors with the AstraZeneca affiliation are full time employees and/or have stock in AstraZeneca. AstraZeneca sponsored this study.

AUTHOR CONTRIBUTIONS

YJL and DS drafted the manuscript. YJL, XY, PG, YG and XN designed and conceived the study. DS, CL and XN acquired and processed the patient samples. XY pathologically reviewed all the patient samples. YX, JQ and YS carried out the *in vitro* experiment. JL and JZ carried out the *in vivo* experiments. YJL, DS, TZ, XS, ZQ and PG interpreted and analysed the data. PZ carried out the statistical analysis. YG and XN supervised the whole study.

REFERENCES

- Asaoka Y, Ikenoue T, Koike K (2011) New targeted therapies for gastric cancer. *Expert Opin Investig Drugs* **20**(5): 595–604.
- Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Ruschoff J, Kang YK (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. *Lancet* **376**(9742): 687–697.
- Brunetto AT, Kristeleit RS, de Bono JS (2010) Early oncology clinical trial design in the era of molecular-targeted agents. *Future Oncol* **6**(8): 1339–1352.
- Chen CT, Kim H, Liska D, Gao S, Christensen JG, Weiser MR (2012) MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric cancer cells. *Mol Cancer Ther* **11**(3): 660–669.
- Davies BR, Logie A, McKay JS, Martin P, Steele S, Jenkins R, Cockerill M, Cartledge S, Smith PD (2007) AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action *in vivo*, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models. *Mol Cancer Ther* **6**(8): 2209–2219.
- Deng N, Goh LK, Wang H, Das K, Tao J, Tan IB, Zhang S, Lee M, Wu J, Lim KH, Lei Z, Goh G, Lim QY, Tan AL, Sin Poh DY, Riahi S, Bell S, Shi MM, Linnartz R, Zhu F, Yeoh KG, Toh HC, Yong WP, Cheong HC, Rha SY, Boussios A, Grabsch H, Rozen S, Tan P (2012) A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. *Gut* **61**(5): 673–684.
- Eder JP, Vande Woude GF, Boerner SA, LoRusso PM (2009) Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. *Clin Cancer Res* **15**(7): 2207–2214.
- Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. *Int J Cancer* **127**(12): 2893–2917.
- Fujimoto-Ouchi K, Sekiguchi F, Yasuno H, Moriya Y, Mori K, Tanaka Y (2007) Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models. *Cancer Chemother Pharmacol* **59**(6): 795–805.
- Graziano F, Galluccio N, Lorenzini P, Ruzzo A, Canestrari E, D'Emidio S, Catalano V, Sisti V, Ligorio C, Andreoni F, Rulli E, Di Oto E, Fiorentini G, Zingaretti C, De Nictolis M, Cappuzzo F, Magnani M (2011) Genetic activation of the MET pathway and prognosis of patients with high-risk, radically resected gastric cancer. *J Clin Oncol* **29**(36): 4789–4795.
- Janjigian YY, Werner D, Pauligk C, Steinmetz K, Kelsen DP, Jager E, Altmannberger HM, Robinson E, Tafe LJ, Tang LH, Shah MA, Al-Batran SE (2012) Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis. *Ann Oncol* **23**(10): 2656–2662.
- Kamangar F, Dores GM, Anderson WF (2006) Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. *J Clin Oncol* **24**(14): 2137–2150.
- Khushalani NI (2012) Phase I and II clinical trials for gastric cancer. *Surg Oncol Clin N Am* **21**(1): 113–128.
- Kim JW, Im SA, Kim M, Cha Y, Lee KH, Keam B, Kim MA, Han SW, Oh DY, Kim TY, Kim WH, Bang YJ (2012) The prognostic significance of HER2 positivity for advanced gastric cancer patients undergoing first-line modified FOLFOX-6 regimen. *Anticancer Res* **32**(4): 1547–1553.
- Kunii K, Davis L, Gorenstein J, Hatch H, Yashiro M, Di Bacco A, Elbi C, Lutterbach B (2008) FGFR2-amplified gastric cancer cell lines require FGFR2 and ErbB3 signaling for growth and survival. *Cancer Res* **68**(7): 2340–2348.
- Lee HE, Kim MA, Lee HS, Jung EJ, Yang HK, Lee BL, Bang YJ, Kim WH (2012) MET in gastric carcinomas: comparison between protein expression and gene copy number and impact on clinical outcome. *Br J Cancer* **107**(2): 325–333.
- Lennerz JK, Kwak EL, Ackerman A, Michael M, Fox SB, Bergethon K, Lauwers GY, Christensen JG, Wilner KD, Haber DA, Salgia R, Bang YJ, Clark JW, Solomon BJ, Iafrate AJ (2011) MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. *J Clin Oncol* **29**(36): 4803–4810.
- Lordick F, Kang YK, Chung HC, Salman P, Oh SC, Bodoky G, Kurteva G, Volovat C, Moiseyenko VM, Gorbunova V, Park JO, Sawaki A, Celik I, Gotte H, Melezinkova H, Moehler M (2013) Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. *Lancet Oncol* **14**(6): 490–499.
- Matsumoto K, Arai T, Hamaguchi T, Shimada Y, Kato K, Oda I, Taniguchi H, Koizumi F, Yanagihara K, Sasaki H, Nishio K, Yamada Y (2012) FGFR2 gene amplification and clinicopathological features in gastric cancer. *Br J Cancer* **106**(4): 727–732.
- Meza-Junco J, Sawyer MB (2012) Metastatic gastric cancer - focus on targeted therapies. *Biologics* **6**: 137–146.
- Ming SC (1998) Cellular and molecular pathology of gastric carcinoma and precursor lesions: A critical review. *Gastric Cancer* **1**(1): 31–50.
- Minuti G, Cappuzzo F, Duchnowska R, Jassem J, Fabi A, O'Brien T, Mendoza AD, Landi L, Biernat W, Czartoryska-Arlukowicz B, Jankowski T, Zuziak D, Zok J, Szostakiewicz B, Foszczynska-Kloda M, Tempinska-Szalach A, Rossi E, Varella-Garcia M (2012) Increased MET and HGF gene copy numbers are associated with trastuzumab failure in HER2-positive metastatic breast cancer. *Br J Cancer* **107**(5): 793–799.
- Nadauld LD, Ford JM (2013) Molecular profiling of gastric cancer: toward personalized cancer medicine. *J Clin Oncol* **31**(7): 838–839.
- Nahta R, Esteva FJ (2006) HER2 therapy: molecular mechanisms of trastuzumab resistance. *Breast Cancer Res* **8**(6): 215.
- Nakamura K, Yashiro M, Matsuoka T, Tendo M, Shimizu T, Miwa A, Hirakawa K (2006) A novel molecular targeting compound as K-samII/FGF-R2 phosphorylation inhibitor, Ki23057, for Scirrhus gastric cancer. *Gastroenterology* **131**(5): 1530–1541.
- Ohtsu A, Shah MA, Van Cutsem E, Rha SY, Sawaki A, Park SR, Lim HY, Yamada Y, Wu J, Langer B, Starnawski M, Kang YK (2011) Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. *J Clin Oncol* **29**(30): 3968–3976.
- Oliner K, Tang R, Anderson A, Lan Y, Iveson T, Donehower R, Jiang Y, Dubey S, Loh E (2012) Evaluation of MET pathway biomarkers in a phase II study of rilotumumab (R, AMG 102) or placebo (P) in combination with epirubicin, cisplatin, and capecitabine (ECX) in patients (pts) with locally advanced or metastatic gastric (G) or esophagogastric junction (EGJ) cancer. *J Clin Oncol* **30**(Suppl): abstr 4005.
- Oliveras-Ferraro C, Corominas-Faja B, Cufi S, Vazquez-Martin A, Martin-Castillo B, Iglesias JM, Lopez-Bonet E, Martin AG, Menendez JA (2012) Epithelial-to-mesenchymal transition (EMT) confers primary resistance to trastuzumab (Herceptin). *Cell Cycle* **11**(21): 4020–4032.
- Pazo Cid RA, Anton A (2013) Advanced HER2-positive gastric cancer: current and future targeted therapies. *Crit Rev Oncol Hematol* **85**(3): 350–362.
- Power DG, Kelsen DP, Shah MA (2010) Advanced gastric cancer—slow but steady progress. *Cancer Treat Rev* **36**(5): 384–392.
- Rodrig S, Sequist LV, Schiller JH, Chen Y, Halim A, Waghorne C, Zahir H, Schwartz B. An exploratory biomarker analysis evaluating the effect of the c-MET inhibitor tivantinib (ARQ 197) and erlotinib in NSCLC patients in a randomized, double-blinded phase 2 study [Abstract] (2012) *Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 March 31–April 4; Chicago, IL, Philadelphia (PA): AACR; Cancer Res* 2012; **72**(8 Suppl): Abstract nr 1729. doi:1538-7445.AM2012-1729.
- Rusnak DW, Allgood KJ, Mullin RJ, Spehar GM, Arenas-Elliott C, Martin AM, Degenhardt Y, Rudolph SK, Haws Jr TF, Hudson-Curtis BL, Gilmer TM (2007) Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb, GW572016) in an expanded panel of human normal and tumour cell lines. *Cell Prolif* **40**(4): 580–594.
- Shan L, Ying J, Lu N (2013) HER2 expression and relevant clinicopathological features in gastric and gastroesophageal junction adenocarcinoma in a Chinese population. *Diagn Pathol* **8**: 76.
- Sheng WQ, Huang D, Ying JM, Lu N, Wu HM, Liu YH, Liu JP, Bu H, Zhou XY, Du X (2013) HER2 status in gastric cancers: a retrospective analysis from four Chinese representative clinical centers and assessment of its prognostic significance. *Ann Oncol* **24**(9): 2360–2364.
- Sierra JR, Tsao MS (2011) c-MET as a potential therapeutic target and biomarker in cancer. *Ther Adv Med Oncol* **3**(1 Suppl): S21–S35.
- Timofeevski SL, McTigue MA, Ryan K, Cui J, Zou HY, Zhu JX, Chau F, Alton G, Karlicek S, Christensen JG, Murray BW (2009) Enzymatic

- characterization of c-Met receptor tyrosine kinase oncogenic mutants and kinetic studies with aminopyridine and triazolopyrazine inhibitors. *Biochemistry* **48**(23): 5339–5349.
- Spigel DR, Ervin TJ, Ramlau R, Daniel DB, Goldschmidt JH, Blumenschein GR, Krzakowski MJ, Robinet G, Clement-Duchene C, Barlesi F, Govindan R, Patel T, Orlov SV, Wertheim MS, Zha J, Pandita A, Yu W, Yauch RL, Patel PH, Peterson AC (2011) Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAB or placebo in combination with erlotinib in advanced NSCLC. *J Clin Oncol* **29**(Suppl): abstr 7505.
- Turner N, Grose R (2010) Fibroblast growth factor signalling: from development to cancer. *Nat Rev Cancer* **10**(2): 116–129.
- Waddell T, Chau I, Cunningham D, Gonzalez D, Frances A, Okines C, Wotherspoon A, Saffery C, Middleton G, Wadsley J, Ferry D, Mansoor W, Crosby T, Coxon F, Smith D, Waters J, Iveson T, Falk S, Slater S, Peckitt C, Barbachano Y (2013) Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. *Lancet Oncol* **14**(6): 481–489.
- Xie L, Su X, Zhang L, Yin X, Tang L, Zhang X, Xu Y, Gao Z, Liu K, Zhou M, Gao B, Shen D, Ji J, Gavine PR, Zhang J, Kilgour E, Ji Q (2013) FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547. *Clin Cancer Res* **19**(9): 2572–2583.

This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License.

Supplementary Information accompanies this paper on British Journal of Cancer website (<http://www.nature.com/bjc>)